business
Rare disease families find roadmap to drug development at bootcamps
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- Developing a new drug can cost a billion dollars and take more than a decade.
- That's a big reason why 95% of the more than 10,000 rare diseases that exist do not have an FDA-approved treatment.
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
Developing a new drug can cost a billion dollars and take more than a decade. That makes investing in new treatments in the rare disease space — where patient populations are small, and the chance of earning a return on that investment even smaller — a risky bet for big pharmaceutical companies.
That's a big reason why 95% of the more than 10,000 rare diseases that exist do not have an FDA-approved treatment.
Article preview — originally published by CNBC. Full story at the source.
Read full story on CNBC →
More top stories
Also covered by
Investing.com
InflaRx stock surges on AAV drug development plan
NPR News
These families help researchers find Alzheimer's treatments. Their network is at risk
The Hindu
HC asks TTD to decide on darshan quota for autoimmune, rare disease patients in 4 months
STAT News
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop